AXQ Capital’s Maravai LifeSciences MRVI Stock Holding History

AXQ Capital’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-20,548	Closed	-$128K	–	1303
2026 Q2	$128K	Sell	20,548 -10,326	-33%	-$44.6K	0.01%	783
2026 Q1	$87.4K	Sell	30,874 -13,120	-30%	-$44.5K	0.01%	886
2025 Q4	$143K	Buy	43,994 +17,135	+64%	+$57.7K	0.03%	619
2025 Q3	$77.1K	Buy	+26,859	New	+$68.6K	0.03%	528
2025 Q2	–	Sell	-35,391	Closed	-$78.2K	–	700
2025 Q1	$78.2K	Buy	+35,391	New	+$140K	0.03%	454
2024 Q3	–	Sell	-37,982	Closed	-$272K	–	537
2024 Q2	$272K	Sell	37,982 -13,093	-26%	-$113K	0.06%	373
2024 Q1	$443K	Sell	51,075 -3,525	-6%	-$23.8K	0.11%	331
2023 Q4	$358K	Buy	+54,600	New	+$353K	0.1%	342

Other funds holding MRVI

GTCR LLC Chicago, Illinois $4.29B AUM 4.12% 1-Year Est. Return

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

First Eagle Investment Management New York $63.7B AUM 20.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $123B AUM 30.05% 1-Year Est. Return

AXQ Capital's MRVI Position: Q3 2026 in Review

AXQ Capital sold out of Maravai LifeSciences (MRVI) in Q3 2026, closing a stake of 20,548 shares — an estimated $128K sold.

AXQ Capital first reported a position in MRVI in Q4 2023 and held it in 8 quarters. The position peaked at $443K in Q1 2024. 146 funds tracked by Wall St. Rank hold MRVI as of Q3 2026.

AXQ Capital reported no remaining Maravai LifeSciences position as of Q3 2026 after selling out during the quarter.
AXQ Capital sold 20,548 Maravai LifeSciences shares in Q3 2026, an estimated $128K.
AXQ Capital first reported a position in Maravai LifeSciences in Q4 2023 and held it in 8 quarters.
AXQ Capital's Maravai LifeSciences position peaked at $443K in Q1 2024.
146 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2026.

Based on AXQ Capital's 13F filing for Q3 2026, filed 12 Nov 2026.